Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | LIPC | P11150 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029439 | 1.00 | CTSA (0.45) | CTSACNR2USP30LIPGADORA2A | |
| SCHEMBL5033733 | 0.86 | CNR2 (0.45) | CNR2USP30LIPGRAB9ACCR2 | |
| SCHEMBL5029598 | 0.81 | RAB9A (0.43) | CNR2USP30LIPGRAB9ACCR2 | |
| SCHEMBL5030277 | 0.78 | RAB9A (0.46) | RAB9ACCR2 | |
| SCHEMBL5033656 | 0.78 | CCR2 (0.51) | RAB9ACCR2 | |
| SCHEMBL5033653 | 0.78 | CCR2 (0.51) | RAB9ACCR2 | |
| SCHEMBL5030274 | 0.78 | RAB9A (0.46) | RAB9ACCR2 | |
| SCHEMBL5027275 | 0.76 | ALDH1A1 (0.56) | CTSACNR2ADORA1RAB9ACCR2 | |
| SCHEMBL5027265 | 0.76 | ALDH1A1 (0.56) | CTSACNR2ADORA1RAB9ACCR2 | |
| SCHEMBL5031903 | 0.72 | IRAK4 (0.55) | CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | CTSA 398/4885CNR2 102/4885USP30 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.